Barcha huquqlar himoyalangan.
0.00
0.00 (0.00%)
Myriad (MYGN) reported earnings 30 days ago. What's next for the stock?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Myriad announces FDA approval for the MyChoice CDx Test as the Companion Diagnostic for Zejula, a PARP inhibitor from GSK, for patients with ovarian cancer
Myriad Genetics delivered a solid Q4 2025 earnings beat, with positive adjusted EPS and strong test volume growth despite modest revenue decline. MYGN's core franchises—Prolaris and hereditary cancer—showed resilience, offsetting reimbursement headwinds in mental health and weakness in prenatal testing. Cost-cutting drove sharply lower operating expenses and narrowed losses, while gross margins remained stable at 70%, signaling operational stabilization.
Myriad Genetics jumps 21% after Q4 earnings beat estimates by 350% and revenues top forecasts, even as gross margin slips and mental health sales decline.
Myriad Genetics, Inc. (MYGN) Q4 2025 Earnings Call Transcript
There is no data to display
